Novel lenses demonstrate modifying retinal contrast slows myopia progression
Click Here to Manage Email Alerts
NEW ORLEANS — Modifying retinal contrast with diffusion optics technology lenses slowed spherical equivalent refraction and axial length over 4 years in children with myopia, according to a presenter at Academy ’23.
“Our clinical trial supports the hypothesis that we can slow myopia progression by modifying the retinal contrast,” Deborah Laughton, BSc, MCOptom, PhD, FBCLA, director of medical affairs for Europe, the Middle East and Africa at SightGlass Vision, said in her presentation on the CYPRESS study.
The 3-year trial was conducted at 14 locations in the U.S. and Canada and included 256 myopic children aged 6 to 10 years, who were randomized to wear T1 or T2 diffusion optics technology (DOT) lenses or standard single-vision control lenses. Of 200 participants who completed the first part of the trial, 98 were invited to complete the second part for an additional year, in which the T1 and control groups continued wearing their original lenses, and those in the T2 group crossed over to T1 lenses.
The DOT lenses work by softening retinal contrast, which researchers hypothesized can slow myopia progression, Laughton said.
In the fourth year of the study, the researchers noticed an unexpected boost in treatment effect, which coincided with school closures due to the COVID-19 pandemic.
“We really think it’s this change in the lifestyle and the schooling of the children during the years 2 and 3 that impacted the treatment effect here,” Laughton said. “If we look outside of this period — if we look at the first year and the last year — we see some really encouraging results.”
In the first year, the spherical equivalent refraction (SER) slowed by 70%, and axial length slowed by 52%, Laughton said. In the final year, the SER slowed by 51%, and the axial length slowed by 35%.
Full-time wearers, or those who did not remove glasses for near-vision activities, had even better results, with 81% slowing of myopia progression in the first year and 51% in the last year.
The researchers reported no serious adverse events or spectacle-related adverse events throughout the study.
Collapse
Laughton D, et al. Control of myopia using diffusion optics technology spectacle lenses: 4-year results. Presented at: Academy; Oct. 11-14, 2023; New Orleans.
Read more about
Click Here to Manage Email Alerts